This is in contrast to the average amount of additional driver mutations seen in other AML subtypes [3], most likely due to the fact that KMT2A is one of the strongest oncogenic drivers and is sufficient to transform healthy hematopoietic stem cells in murine models as a single molecular lesion [33]. Here, KMT2A is linked to acute myeloid leukemia.